DxTerity Diagnostics and the NEAT™ platform have been recognized for providing a pathway for incorporating genetic testing—even complex gene signatures—into routine medical care. A select listing of news reports is listed below. For additional information, contact news@dxterity.com.

Dirty-bomb test for terror may aid cancer research (AP)

Duke awarded up to $43 million to develop test for dirty bomb and radiation exposure

Premier Biosoft Delivers Version 7.5 including DxTerity's NEAT™

SCRI to Use DxTerity Reagents in Cardiac Test

DxTerity Diagnostics and City of Hope Announce Therapeutics Collaboration